- Histologically proven Gastrointestinal Stomal Tumor (GIST) that is not amenable to
standard therapy
- Undergone screening and found to be ineligible for participation in ongoing SU011248
clinical studies
- Patient judged to have potential to derive clinical benefit from SU011248 treatment by
the treating physician
- Failed prior treatment with imatinib mesylate, defined as either progression of
disease or significant toxicity during treatment with imatinib mesylate that precluded
further treatment
- Male or Female, 18 years or older
- Resolution of all acute toxicities of prior therapies
- Adequate organ function
- Symptomatic congestive heart failure, myocardial infarction, or coronary artery bypass
graft in the last 6 months, or ongoing severe or unstable angina or any unstable
arrhythmia requiring medication
- Symptomatic central nervous system metastases
- Serious acute or chronic illness
- Current treatment on another clinical trial
- Pregnant or breastfeeding.